Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Lundin, J
Kimby, E
Bjorkholm, M
Celsing, F
Hale, G
Hjalmar, V
Merup, M
Petrescu, A
Tullgren, O
Waldmann, H
Mellstedt, H
Osterborg, A
机构：
[1] Karolinska Inst, S-10401 Stockholm, Sweden
[2] Therapeut Antibody Ctr, Oxford, England
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3215
引用
收藏
页码：772A / 772A
页数：1
相关论文
共 50 条
  • [31] Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes
    Frankfurt, Olga
    Ma, Shuo
    Gordon, Leo
    Winter, Jane N.
    Horowitz, Jeanne M.
    Rademaker, Alfred
    Weitner, Bing Bing
    Peterson, Loann C.
    Altman, Jessica K.
    Tallman, Martin S.
    Petrich, Adam
    Rosen, Steven T.
    LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 315 - 323
  • [32] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
    Stilgenbauer, S
    Winkler, D
    Kröber, A
    Kienle, D
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    BLOOD, 2004, 104 (11) : 140A - 140A
  • [33] Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia - Efficacy of in vivo purging by alemtuzumab (Campath-1H)
    Galimberti, S
    Cervetti, G
    Cecconi, N
    Fazzi, R
    Pacini, S
    Guerrini, F
    Manetti, C
    Caracciolo, F
    Petrini, M
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (05) : 389 - 393
  • [34] SUBCUTANEOUS ADMINISTRATION OF ALEMTUZUMAB (CAMPATH-1H) IS WELL TOLERATED AND EFFECTIVE
    Lawrence, J.
    Blesing, J.
    Filipovich, A.
    Jodele, S.
    Mehta, P.
    Davies, S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 153 - 154
  • [35] Phase II study of alemtuzumab (Campath-1H) in patients with advanced mycosis fungoides/Sezary syndrome.
    Hagberg, H
    Lundin, J
    Repp, R
    Eriksson, M
    Juliusson, G
    Norberg, B
    Wiklund, T
    Cavalin-Stahl, E
    Osterborg, A
    BLOOD, 2001, 98 (11) : 806A - 806A
  • [36] Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia
    Nguyen, DD
    Cao, TM
    Dugan, K
    Starcher, SA
    Fechter, RL
    Coutre, SE
    CLINICAL LYMPHOMA, 2002, 3 (02): : 105 - 110
  • [37] A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    William, Basem M.
    Brillhart, Kaylee
    Afable, Manuel
    Bakalarz, Kristen
    Cooper, Brenda
    Lazarus, Hillard M.
    Gerson, Stanton L.
    Creger, Richard
    Nagabhushanam, Kalyanam
    Grote, James
    Fu, Pingfu
    Kunati, Sandeep
    Yang, Shuming
    Xu, Yan
    Woost, Philip
    Jacobberger, James
    de Lima, Marcos
    Caimi, Paolo
    BLOOD, 2018, 132
  • [38] Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL).
    Sharman, Jeff Porter
    Yimer, Habte Aragaw
    Boxer, Michael
    DiBella, Nicholas
    Babu, Sunil
    Li, Jia
    Mun, . . . Yong Jun
    Skettino, Sandra L.
    Danilov, Alexey Valeryevich
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL)
    Rawstron, AC
    Davies, FE
    Evans, PA
    Jamil, A
    Galvin, MC
    Haynes, AP
    Hale, G
    Morgan, GJ
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 46 - 46
  • [40] CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL).
    Rawstron, AC
    Davies, FE
    Evans, P
    Morgan, GJ
    Jamil, A
    Galvin, MC
    Haynes, AP
    Hale, G
    Hillmen, P
    BLOOD, 1997, 90 (10) : 2356 - 2356
12345